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Breast cancer is the most common type of cancer among American women, and remains
the second leading cause of cancer-related death for female in the United States. It has
been known that several signaling pathways and various factors play critical roles in the
development and progression of breast cancer, such as estrogen receptor, Notch, PTEN,
human epidermal growth factor receptor 2, PI3K/Akt, BRCA1, and BRCA2. Emerging evi-
dence has shown that the F-box protein S-phase kinase associated protein 2 (Skp2) also
plays an important role in the pathogenesis of breast cancer.Therefore, in this brief review,
we summarize the novel functions of Skp2 in the pathogenesis of breast cancer. Moreover,
we provide further evidence regarding the state of our knowledge toward the development
of novel Skp2 inhibitors especially natural “chemopreventive agents” as targeted approach
for the prevention and/or treatment of breast cancer.
Keywords: Skp2, breast cancer, therapy, signaling pathway, ubiquitination, cell cycle
INTRODUCTION
Breast cancer is the most common female malignancy, and the
second leading cause of cancer-related death after lung cancer in
the United States (Siegel et al., 2011). The American Cancer Soci-
ety estimates that approximately 230,480 American women will
be diagnosed with breast cancer and almost 40,000 will die from
it in 2011 (Siegel et al., 2011). Breast cancer has been clinically
characterized by the expression of hormone and growth factor
receptors such as estrogen receptor (ER), progesterone receptor
(PR), and human epidermal growth factor receptor 2 (Her2; Lin
et al., 2010). Approximately 70% of breast cancer patients have
elevated expression of ER and PR, while 20% of breast tumors
have overexpression of Her2. The remaining 10% of breast cancer
cases are classiﬁed as triple-negative breast cancers due to the lack
of expression of ER, PR, and Her2 (Lin et al., 2010). Even though
breast cancer recurrence rates have been signiﬁcantly decreased
due to early detection and adjuvant therapies, breast cancer still
causes high mortality. Current therapies for breast cancer include
surgery, radiation, chemotherapy, hormonal, and biological ther-
apies (Lin et al., 2010). Despite improved treatments that have
been achieved recently, many breast tumors are not eradicated
effectively due to their intrinsic or acquired resistance, or relapse
following initial response, resulting in metastatic disease at later
stages that leads to patient death (Lin et al., 2010). Therefore, this
disappointing outcome suggests that further understanding of the
molecularmechanisms underlying the development of breast can-
cer,especially the critical events of themetastatic spread, is essential
to identify new therapeutic targets for achieving better treatment
of breast cancer.
In recent years, it has been demonstrated that multiple cellular
signaling pathways including the ER, PR, epidermal growth factor
receptor (EGFR), breast cancer susceptibility gene (BRCA), PI3K
(phosphatidylinositol 3-kinase), PTEN (phosphatase and tensin
homolog on chromosome 10), mammalian target of rapamycin
(mTOR), MAPK (mitogen-activated protein kinases), androgen
receptor (AR), Akt, nuclear factor-κB (NF-κB), receptor of acti-
vated nuclear factor kappa ligand (RANKL),Wnt, sonic hedgehog
(SHH), platelet-derived growth factor (PDGF), and Notch path-
ways have been found to play important roles in the development
and progression of breast cancer (Foley et al., 2010; Haagenson
and Wu, 2010; Nahta and O’Regan, 2010; Narod, 2010; Prosperi
and Goss, 2010; Rosen et al., 2010; Visbal and Lewis, 2010; Guo
et al., 2011; Hernandez-Aya and Gonzalez-Angulo, 2011; O’Regan
and Hawk, 2011). It is worth noting that exact mechanisms by
which breast cancer arises remain largely unclear. Emerging evi-
dence has demonstrated that S-phase kinase associated protein
2 (Skp2) is critically involved in the pathogenesis of breast can-
cer (Hulit et al., 2006; Sun et al., 2007; Fujita et al., 2008; Voduc
et al., 2008; Chan et al., 2010b). Therefore, in this review arti-
cle, we will provide an overview on the role of Skp2 oncoprotein,
and summarizing recently published literatures that highlight the
novel roles of Skp2 in mammary tumorigenesis. Finally, we will
also summarize approaches to inhibit Skp2 andwould suggest that
Skp2 could be a promising therapeutic target in combating human
breast cancer.
Skp2 IS ONE OF THE COMPONENTS OF THE SCF E3 LIGASE
COMPLEX
S-phase kinase associated protein 2 belongs to ubiquitin–
proteasome system (UPS) that plays vital roles in regulating many
biological processes by controlling the timely turn-over of proteins
(Frescas and Pagano, 2008). UPS includes three types of enzymes
for exerting UPS function via a cascade of enzymatic reactions
(Nalepa et al., 2006). The three enzymes are ubiquitin-activating
enzyme (E1), ubiquitin-conjugating enzyme (UBC, also known as
E2), and ubiquitin ligase (E3; Weissman et al., 2011). The initial
step is to add ubiquitin to E1 and subsequently transfer of it to the
E2 enzyme. The ubiquitin-charged E2 then interacts with E3 and
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transfers the ubiquitin onto the substrate, leading to the formation
of a mono-ubiquitin or polyubiquitin chain due to the consecu-
tive addition of ubiquitin moieties to target proteins (Nakayama
and Nakayama, 2006). It is evident that the speciﬁcity of substrate
selection depends on the E3, leading to substrate degradation by
the 26S proteasome (Nakayama and Nakayama, 2006). This bio-
chemical feature could explain why deregulation of E3 has been
frequently found in carcinogenesis, whereas the function of E1
and E2 in carcinogenesis documented only few published reports
(Okamoto et al., 2003).
It is known that Skp2 is one of the components of the Skp1–
Cullin1–F-box (SCF) E3 ligase complex. The SCF complexes com-
prise a family of multi-subunit E3 ubiquitin ligases that target
selected proteins for destruction by the 26S proteasome degrada-
tion (Frescas and Pagano, 2008). SCF complexes contain several
constant core proteins such as Skp1, Rbx1 (also known as ROC1),
Cullin1, and a variable subunit called F-box protein (Frescas and
Pagano, 2008). F-box protein that functions as a receptor for target
proteins can bind to a speciﬁc subset of substrates for promoting
their degradation (Nakayama and Nakayama, 2006). So far, more
than 70 putative F-box proteins encoded in the human genome
have been found (Nakayama and Nakayama, 2006). It is clear
that Skp2 is an F-box protein of the SCF complex (Figure 1).
Because Skp2 is originally discovered with Skp1 associated with
the S-phase kinase Cdk2/cyclin A, it was named as Skp2 (Frescas
and Pagano, 2008). Among the many F-box proteins, Skp2 has
been well-characterized and it has been shown to be involved in
carcinogenesis.
Skp2 IS A PROTO-ONCOPROTEIN
S-phase kinase associated protein 2 is the speciﬁc factor of the
SCFskp2 E3 ligase involved in cell cycle progression through degra-
dation of its targets (Bashir and Pagano, 2004; Frescas and Pagano,
2008). For example, Skp2 is essential for p27 degradation and
thereby limiting cells in G1 phase, prior to entry into S-phase
(Amati andVlach, 1999; Carrano et al., 1999; Tsvetkov et al., 1999).
This ﬁnding raised the question of whether the observed lower
FIGURE 1 | Illustration of the SCFskp2 complex.The SCF
(Skp1–Cullin1–F-box) E3 ubiquitin ligase complex consists of four
components: Skp1, Rbx1, Cullin1, and the variable F-box protein. In SCFskp2,
the F-box protein component is Skp2. Skp2 recognizes the targeted
proteins and makes the ubiquitin transfer to the substrate protein by UBC
(the E2 enzyme). The addition of polyubiquitin targets substrates for
degradation by the 26S proteasome. The known substrates of Skp2 include
p21, p27, p57, p130, Tob1, FOXO1, and c-Myc.
levels of p27 are caused by overexpression of Skp2 in human can-
cers. Indeed, accumulating evidence has shown that Skp2 expres-
sion is inversely correlated with p27 levels in different types of
human malignancies (Hershko and Shapira, 2006). To date, in
addition to p27, speciﬁc substrates of Skp2 have also been identi-
ﬁed which include p57 (Kamura et al., 2003), p21 (Yu et al., 1998),
p130 (Tedesco et al., 2002; Bhattacharya et al., 2003), Tob1 (Hira-
matsu et al., 2006), FOXO1 (Huang et al., 2005), and many others
(Michel and Xiong, 1998; Yu et al., 1998; Nakayama et al., 2000).
These substrates are involved in many cellular processes such as
cell cycle regulation, proliferation, differentiation, apoptosis, and
survival. Without a doubt, Skp2 has important functions in the
regulation of these cellular processes due to degradation of its
substrates,most of which are tumor suppressor proteins (Gstaiger
et al., 2001). Because Skp2 is responsible for the degradation of
the above-mentioned tumor suppressor proteins, Skp2 is thought
to function as oncoprotein (Gstaiger et al., 2001).
Many studies have shown that overexpression of Skp2 is
observed in a variety of human cancers, including lymphomas
(Seki et al., 2003), prostate cancer (Wang et al., 2011a), colorectal
cancer (Li et al., 2004),melanoma (Rose et al., 2011), nasopharyn-
geal carcinoma (Fang et al., 2009;Xu et al., 2011),pancreatic cancer
(Schuler et al., 2011), and breast carcinomas (Radke et al., 2005;
Zheng et al., 2005). Moreover, Skp2 has been found to be a prog-
nostic marker in multiple cancers. For example, overexpression of
Skp2 is associated with late metastases to lymph nodes leading to
poor survival in colorectal cancer (Li et al., 2004). A separate study
showed that overexpression of Skp2 was associated with signiﬁ-
cantly poorer tumor differentiation and reduced patient survival
in gastric cancer (Ma et al., 2005). Similarly, Skp2 expression was
correlated with histological grade and tumor size in hepatocellular
carcinoma (Lu et al., 2009). Moreover, elevated Skp2 expression
is related with tumor metastasis in melanoma (Rose et al., 2011),
lymphoma, oral squamous cell carcinomas (Tosco et al., 2011),
pancreatic cancer (Einama et al., 2006), and prostate cancer (Wang
et al., 2011a). Furthermore, Skp2 expression has been considered
as a biomarker for poor prognosis in breast cancer (Voduc et al.,
2008), melanoma (Rose et al., 2011), and nasopharyngeal carci-
noma (Xu et al., 2011). Interestingly, one recent report showed that
Skp2 mediates resistance of pancreatic cancer cell lines toward the
TRAIL (tumor factor-related apoptosis-inducing ligand)-induced
apoptosis (Schuler et al., 2011). Taken together, Skp2 is believed
to be a proto-oncoprotein. In the following paragraphs, we will
discuss the role of Skp2 in the breast cancer progression.
THE ROLE OF Skp2 IN DEVELOPMENT AND PROGRESSION OF
BREAST CANCER
A growing body of literature strongly suggests that Skp2 plays crit-
ical roles in the breast tumorigenesis. For example, Skp2 has been
reported to be overexpressed in a subset of breast carcinomas with
low level of p27 expression (Signoretti et al., 2002). Emerging evi-
dence also reveals that Skp2 plays important roles in cell growth,
apoptotic cell death, invasion, and metastasis in human breast
cancer (Zheng et al., 2005; Sonoda et al., 2006). Multiple signal-
ing pathways, such as phosphatidylinositol 3-kinase (PI3K)/Akt
(Gao et al., 2009a), ERK (extracellular signal-regulated kinase;
Lin and Yang, 2006), peroxisome proliferator-activated receptor-γ
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(PPARγ; Zaytseva et al., 2008), IGF-1 (insulin-like growth factor-
1; Lu et al., 2004), and mTOR (Shapira et al., 2006) signaling have
been discovered to cross-talk with Skp2, and thus it is believed
that the cross-talks between Skp2 and these signaling pathways
may play important roles in breast cancer. However, the molecu-
lar mechanism(s) by which Skp2 facilitates breast cancer remain
largely elusive. Here, we will discuss some recent advances in
the understanding on the role of Skp2 in breast tumor progres-
sion. Therefore, in the following sections, we will summarize the
results of emerging studies on the Skp2 as well as its therapeutic
implication in human breast cancer.
Skp2 IS OVEREXPRESSED IN BREAST CANCER
It has been widely accepted that Skp2 is frequently overexpressed
in a variety of human cancers including breast cancer. For instance,
both Skp2mRNA and protein display elevated levels in breast can-
cer cell lines and primary breast tumors (Radke et al., 2005; Fujita
et al., 2008). Speciﬁcally, using microarray analysis and immuno-
histochemistry, Pagano’s group found that higher levels of Skp2
are present more frequently in ER-negative tumors than in the
ER-positive cases (Signoretti et al., 2002). Moreover, Skp2B, an
isoform of Skp2, is also overexpressed in breast cancer cell lines
and primary breast tumors (Radke et al., 2005). Since Skp2 is over-
expressed in human breast cancer, inhibition of Skp2 could be a
promising therapeutic strategy for breast cancer treatment.
Skp2 PROMOTES CELL GROWTH IN BREAST CANCER
Emerging evidence is accumulating showing that Skp2 promotes
cancer cell growth including breast cancer cell growth. For exam-
ple, down-regulation of Skp2 by RNA interference signiﬁcantly
inhibited cell proliferation in MCF-7 breast cancer cells (Sun
et al., 2007). Treatment with Skp2 siRNA followed by treat-
ment with epirubicin further inhibited the proliferation of breast
cancer cell lines (Sun et al., 2007). Consistent with the role of
Skp2 in cell growth, Signoretti et al. (2002) found that inhibi-
tion of Skp2 induced a decrease of adhesion-independent growth
in both ER-positive and ER-negative breast cancer cells. A study
from Wan’s group has also shown that overexpression of Skp2
enhanced cell proliferation in normal breast cell line MCF10A,
while depletion of Skp2 reduces cellular growth in breast can-
cer cell line (Fujita et al., 2008). Lee and McCormick (2005) also
found similar results, which showed that down-regulation of Skp2
inhibits the in vitro growth of glioblastoma cells.Moreover, knock-
down of endogenous Skp2 by siRNA treatment also inhibited
the in vivo tumor growth in nude mice (Sun et al., 2007). Fur-
thermore, xenograft expressing high levels of Skp2B grows faster
than xenograft expressing low levels of Skp2B (Radke et al., 2005),
suggesting that Skp2B could also promote breast tumor growth.
Recently, it has been found that Skp2B interacts with the REA
(repressor of estrogen receptor activity) and that overexpression
of Skp2B leads to a decreased REA levels, suggesting that Skp2B
contributes to breast cancer in part by modulating the activity of
the ER (Umanskaya et al., 2007). More recently, Chander et al.
(2010) demonstrated that Skp2B attenuates the p53 activity by
degradation of prohibitin, suggesting that his effect is independent
of p300 in breast cancer.
Skp2 INHIBITS CELL APOPTOSIS IN BREAST CANCER
Inhibition of cell growth by down-regulation of Skp2 raised
one question of whether the observed cell growth inhibition is
caused by a possible increase in cellular apoptosis. Multiple stud-
ies have addressed this question. Indeed, Skp2 has been found to
be involved in regulating cellular apoptosis in various types of
human cancer cells (Kitagawa et al., 2008). Kitagawa et al. (2008)
demonstrated that reducing the expression of Skp2 increased
DNA-damage-mediated apoptosis in multiple cancer cells, while
overexpression of Skp2 suppressed p53-mediated apoptosis. The
reason is that Skp2 suppressed p300-mediated acetylation of p53
and subsequent transactivation ability of p53 through forming a
complexwithp300 (Kitagawa et al., 2008). It has also been reported
that down-regulation of Skp2 caused apoptosis via induction of
p27 in glioblastoma cells (Lee and McCormick, 2005). More-
over, down-regulation of both Skp2 and p27 increased apoptosis
synergistically (Lee and McCormick, 2005). Huang et al. (2005)
also found that overexpression of Skp2 inhibits transactivation of
FOXO1 and abolishes the induced effect of FOXO1 on cell apop-
tosis in prostate cancer. Similar trends were found in breast cancer
cell lines. For example, in breast cancer MCF-7 cells, knockdown
of Skp2 by RNAi increased cellular apoptosis (Sun et al., 2007).
Taken together, these results indicate that Skp2 could inhibit cell
apoptosis in breast cancer cells. However, more thorough stud-
ies are required to fully understand the underlying molecular and
signaling events by which Skp2 inﬂuences the cellular apoptotic
decision.
Skp2 REGULATES CELL CYCLE IN BREAST CANCER
The cell cycle is tightly controlled by multiple regulatory mech-
anisms to ensure ordered and coordinated cell cycle progression.
It is known that a major mechanism to ensure the orchestrated
cell cycle is to degrade key regulators governing cell cycle progres-
sion by the UPS. SCF has been considered to be a major driving
force controlling proper cell cycle progression through ubiqui-
tination of G1 cyclins and CDK inhibitors (Skaar and Pagano,
2009). For example, Skp2 targets numerous substrates for degra-
dation, many of which are negative cell cycle regulators such as
p27 (Carrano et al., 1999; Tsvetkov et al., 1999), p57 (Kamura
et al., 2003), p21 (Yu et al., 1998), p130 (Tedesco et al., 2002;
Bhattacharya et al., 2003), and FOXO1 (Huang et al., 2005). There-
fore, Skp2 has been found to correlate with dysregulation of cell
cycle in human cancers including breast cancer. We have dis-
covered that Akt regulates cell cycle through modulating Skp2
activity and its destruction by APC/Cdh1 (Gao et al., 2009a,b).
Fujita et al. (2008) found that overexpression of Skp2 in MCF10A
breast epithelial cells signiﬁcantly elevated the fraction of cells in
S-phase, suggesting that an increase in Skp2 protein levels could
lead to an aberrant cell cycle. Consistent with these ﬁndings, the
fraction of cells in S-phase was signiﬁcantly reduced in Skp2-
depleted MCF-7 breast cancer cells (Fujita et al., 2008). Moreover,
Skp2 expression abrogates antiestrogen-mediated cell cycle arrest
in hormone-dependent breast epithelial cancer cells (Signoretti
et al., 2002). Further research toward exploration of the molecular
mechanisms by which Skp2 regulates cell cycle requires in-depth
investigations.
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Skp2 PROMOTES TUMOR METASTASIS IN BREAST TUMOR
S-phase kinase associated protein 2 overexpression has been cor-
related with tumor progression such as stage and recurrence in
human cancers (Einama et al., 2006), indicating that Skp2 may
be important in cancer cell migration, invasion, and metasta-
sis. Many studies have shown the positive relationship between
Skp2 expression and tumor metastasis in human cancers (Tosco
et al., 2011). For example, Tosco et al. (2011) found the correlation
between Skp2 expression and nodal metastasis in oral squamous
cell carcinomas. Hung et al. (2010) reported that Skp2 overex-
pression increased the expression of MMP-2 and MMP-9, leading
to cell invasion in lung cancer cells. Consistent with this notion,
Einama et al. (2006) also found that higher level Skp2 expression
was correlated with the extent of lymph node metastasis in pan-
creatic ductal adenocarcinoma. Moreover, overexpression of Skp2
was detected more frequently in tumors metastatic to the axillary
lymph nodes in breast cancer (Zheng et al., 2005), indicating that
Skp2 could promote breast tumormetastasis. Recently, Lin’s group
identiﬁed one mechanism by which Skp2 increases tumor metas-
tasis. Their elegant work demonstrated that Skp2 cooperates with
Myc to induce RhoA transcription via recruiting Miz1 and p300
to the RhoA promoter (Chan et al., 2010a). Since RhoA plays a
crucial role in cancer metastasis, deﬁciency of Skp2–Myc–Miz1–
p300 transcriptional complex led to impaired RhoA expression,
resulting in the inhibition of cell migration, invasion, and sub-
sequent breast cancer metastasis (Chan et al., 2010a). Moreover,
deﬁciency of Skp2 profoundly restricted breast cancer metastasis
to the lung,whereas overexpressionof Skp2promoted themetasta-
tic events (Chan et al., 2010a), suggesting a critical role for Skp2
in promoting breast cancer metastasis.
Skp2 PREDICTS FOR POOR PROGNOSIS IN BREAST CANCER
It has been reported that there is a statistically signiﬁcant asso-
ciation between Skp2 expression levels and breast tumor grades.
Moreover, high expression levels of Skp2 are associated with poor
survival (Signoretti et al., 2002). Furthermore, Voduc et al. (2008)
found that the combination of Skp2 and high cyclin E expression
predicts poor prognosis in breast cancer and it is associated with
high risk features. Davidovich et al. (2008) also demonstrated that
Skp2 expression was inversely related to p27 levels, tumor grade, as
well as expression of ER andPR. Both Skp2 andp27were suggested
to be accurate prognostic markers for disease-free and overall sur-
vival in breast cancer. Interestingly, one study showed that low
p27 level and high Skp2 level were not associated with disease-free
survival in breast cancer, although low p27 and high Skp2 were
related to unfavorable prognostic factors including larger tumor
size, higher grade tumor, ER- and PR-negative, and Her2 overex-
pression (Ravaioli et al., 2008). Taken together, it is obvious that
further in-depth investigations are needed to conﬁrm whether
Skp2 could be a promising prognostic marker for breast cancer
patients or not.
Skp2 IS INVOLVED IN DRUG RESISTANCE IN BREAST CANCER
Chemotherapy is the most important treatment strategy for
human cancers including breast cancer. However, chemother-
apy often fails to cure cancer due to the acquisition of drug
resistance phenotype of cancer cells (Wang et al., 2010b). Thus,
increasing drug sensitivity could offer better treatment for human
cancer patients (Wang et al., 2011b). Recently, several studies
have shown that Skp2 is involved in drug resistance in human
cancers including breast cancer (Ishii et al., 2004; Davidovich
et al., 2008; Schuler et al., 2011). A study from Schneider’s group
showed that Skp2 mediates resistance of pancreatic cancer cells
toward TRAIL (tumor necrosis factor-related apoptosis-inducing
ligand)-induced apoptosis (Schuler et al., 2011). Ishii et al. (2004)
reported that overexpression of Skp2 increased chemoresistance
against camptothecin, cisplatin, and AG1478 in human lung can-
cer cells. In support of this notion, similar trend was also found
in breast cancer. Davidovich et al. (2008) demonstrated that high
preoperative expression of Skp2 was correlated with resistance to
cyclophosphamide/doxorubicin/5-ﬂuorouracil therapy in 94% of
breast cancer patients. Interestingly, overexpression of Skp2 is not
associated with resistance to docetaxel in breast cancer patients
(Davidovich et al., 2008), suggesting that Skp2 expression may
be a useful marker for predicting response to doxorubicin-based
preoperative chemotherapy (Davidovich et al., 2008). However,
Ravaioli et al. (2008) found that the relative effects of chemo-
endocrine versus endocrine therapy were similar regardless of
the Skp2 expression status. Therefore, in order to better under-
stand the precise role of Skp2 and its interrelationship with drug
resistance, further in-depth investigations are required.
Skp2 CROSS-TALKS WITH OTHER MAJOR SIGNALING
PATHWAYS IN BREAST CANCER
Although the molecular mechanism(s) by which Skp2 induces
tumor growth has not been fully elucidated, multiple oncogenic
pathways, such as mTOR, ERK, IGF-1, PPARγ, PI3K/Akt, and
FoxP3 have been reported to cross-talk with Skp2 (Lu et al., 2004;
Lin and Yang, 2006; Shapira et al., 2006; Zaytseva et al., 2008; Gao
et al., 2009a). Thus, cross-talks between Skp2 and other pathways
could play critical roles in mammary tumorigenesis. Interestingly,
recent ﬁndings suggest that the tumor suppressor function of
BRCA1 depends on its BRCT (BRCAC terminus) phosphoprotein
binding motif, but not its E3 ligase activity (Shakya et al., 2011).
Recently it was reported that Skp2 could modulate the activity of
p53 in an E3 ligase-independent manner (Kitagawa et al., 2008),
indicating that Skp2 could exert its oncogenic function in both
an E3 ligase-dependent and independent manner. In the follow-
ing paragraphs, we will discuss some recent advances on the role
of Skp2 in tumor progression, especially its cross-talk with other
signaling pathways.
THE ROLE OF mTOR PATHWAY IN THE REGULATION OF Skp2
The cross-talk between mTOR pathway and Skp2 pathway has
been reported recently (Pene et al., 2002; Shapira et al., 2006).
It is known that mTOR plays an important role in the regula-
tion of cellular homeostasis, cell growth, and survival pathways
(Bjornsti and Houghton, 2004). In order to fulﬁll the regulatory
function, mTOR kinase assembles into two distinct complexes
(mTORC1 andmTORC2). ThemTORC1 consists of mTOR,Rap-
tor, proline-rich Akt substrate of 40 kDa (PRAS40), and G-protein
β-subunit-like protein (GβL). The well-characterized mTORC1
kinase substrates include S6K (p70 S6 ribosomal kinase) and phos-
phorylated 4E-binding protein 1 (4E-BP1; Bjornsti andHoughton,
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2004). The mTORC2 is composed of mTOR, Rictor, GβL, pro-
tein observed with Rictor-1 (PROTOR), and stress-activated pro-
tein kinase interacting protein 1 (Sin1; Bjornsti and Houghton,
2004). Interestingly, the Raptor-containing complex is sensitive to
rapamycin and regulates cell proliferation through phosphorylat-
ing S6K and 4E-BP1, whereas the Rictor-containing complex is
not sensitive to rapamycin (Hay and Sonenberg, 2004; Inoki et al.,
2005).
Recently, the mTOR kinase has emerged as a critical player in
the regulation of Skp2 (Shapira et al., 2006). Rapamycin, which
inhibits the mTOR by directly binding the mTORC1, signiﬁcantly
decreased the expression of Skp2 both at mRNA and protein lev-
els in a dose and time-dependent manner in breast cancer cell
lines (Shapira et al., 2006). Moreover, it was found that nega-
tive effect of rapamycin on Skp2 expression has a critical role
in rapamycin-mediated cell growth and G1 arrest (Shapira et al.,
2006). Furthermore, rapamycinpromoted thedegradationof Skp2
and down-regulated the expression of the APC/C inhibitor Emi1
in breast cancer (Shapira et al., 2006), indicating that Skp2 could
be a novel target for mediating the effects of rapamycin; however,
themolecularmechanismbywhichmTOR regulates Skp2 remains
to be elucidated.
ERK AND ITS ROLE IN Skp2 SIGNALING
Multiple studies have shown that ERK activities are up-regulated
inmany human cancers including breast cancer, and elevated ERK
activity in human tumors has been correlatedwith poor prognosis,
demonstrating that ERKmay play a crucial role in human tumori-
genesis (KohnoandPouyssegur,2006). It is known that ERK family
includes ERK1 and ERK2, which belong to MAPK super family
that regulates cell cycle progression, cell proliferation, differenti-
ation, survival, and apoptosis (Kolch, 2005). Activation of MAPK
requires dual phosphorylation by speciﬁcMAPK kinases (MKKs),
and dephosphorylation by protein phosphatases, includingMAPK
phosphatases (MKPs; also known as dual-speciﬁcity phosphatase,
DUSP; Seger and Krebs, 1995). It is well accepted that many differ-
ent stimuli such as growth factors or carcinogens could activate the
ERKpathway, leading to the activation of its targeted proteins such
as downstream kinases and transcription factors that regulates
the expression of speciﬁc genes and their activators/modulators
(Roberts and Der, 2007; Shaul and Seger, 2007).
Recently, it has been reported that Skp2 is involved in ERK
pathway (Lin and Yang, 2006). Lin and Yang (2006) veriﬁed that
Skp2 participated in the ERK-directed ubiquitination and prote-
olysis of MKP-1, suggesting that ERK activity could be controlled
via MKP-1 proteolysis in cooperation with Skp2. Consistent with
this notion, suppression of Skp2 expression resulted in DUSP-1
up-regulation in human hepatocellular carcinoma (Calvisi et al.,
2008). Furthermore, the cooperation between ERK and Skp2
has also been found in human breast cancer whereby synergis-
tic activity of the two oncogenes has been shown to increase p27
degradation (Foster et al., 2003). Moreover, Foster et al. (2003)
showed that estrogens elicit down-regulationof p27 throughSkp2-
dependent and -independent mechanisms and could depend on
p27 localization requiring the participation of other mediators
of the Ras/Raf-1/ERK signaling pathway in breast cancer cells.
However, it remains to be determined how Skp2 regulates the ERK
activation in human breast cancers and the biological consequence
of this regulation requires further investigation.
PI 3K/Akt IN RELATION TO THE Skp2 PATHWAY
The PI3K/Akt pathway has been reported to be involved in Skp2
pathway (Gao et al., 2009a). It has been well documented that
Akt is a serine/threonine protein kinase, which is downstream of
PI3K in response to growth factor stimulation (Hennessy et al.,
2005). The Akt family of kinase includes three closely related
isoforms designed as Akt1/PKBα, Akt2/PKBβ, and Akt3/PKBγ.
Activated Akt promotes cell survival by suppressing apoptosis
through promoting the phosphorylation and subsequent cyto-
plasmic localization of many downstream pro-apoptotic protein
targets including Bad and Forkhead transcription factors such as
FOXO1 and FOXO3a (Hennessy et al., 2005). In addition,Akt also
modulates apoptosis indirectly by inﬂuencing the activities of sev-
eral transcription factors such as NF-κB and CEBP (cyclic AMP-
responsive element binding protein; Franke, 2008). Enhanced Akt
signaling can also promote cell growth by inhibition of negative
cell cycle regulators p21 and p27 (Franke, 2008). Thus, Akt has
been believed to be a promising target for cancer prevention and
treatment (Fresno Vara et al., 2004).
It has been reported that PI3K/Akt regulates p27 expression via
Skp2 in human cancer (Van Duijn and Trapman, 2006). Recently,
we andother groupsdiscovered thatAkt controls Skp2 stability and
the subcellular localization of Skp2 (Gao et al., 2009a; Lin et al.,
2009). First of all, the positive correlation between Skp2 expression
andAkt activitywas found in apanel of breast cancer cell lines (Gao
et al., 2009a).Moreover, inhibition of Akt1 activity in breast cancer
cells caused down-regulation of Skp2 expression, indicating that
elevated Akt activity could be one major cause of the observed
up-regulation of Skp2 in breast cancer (Gao et al., 2009a). Fur-
ther research toward exploration of the molecular mechanisms by
which Akt promotes cytoplasmic localization of Skp2 still requires
further attention.
IGF AND ITS CROSS-TALK WITH THE Skp2 PATHWAY
It is widely accepted that IGF-1 could bind to its receptors includ-
ing IGF-1 receptor (IGF1R) and insulin receptor. In addition,
IGF-1 has been shown to bind and interact with the IGFBPs (IGF-
1 binding proteins), of which there are six identiﬁed members
(IGFBP1-6) so far (Grimberg, 2003). After binding to the IGF1R,
IGF-1 initiates cellular signaling such as activation of PI3K/Akt
signaling pathway and/or Ras/Raf/MAPK pathway, which inﬂu-
ences cell proliferation, survival, and apoptosis (Clayton et al.,
2011). Therefore, the increased level of IGF-1 promotes cell pro-
liferation, inhibits apoptosis, and enhances angiogenesis, all are
involved in the development and progression of human cancers
(Heidegger et al., 2011). A recent study has shown that IGF-
1 regulates the expression of Skp2 in breast cancer (Lu et al.,
2004). Lu and colleagues found that IGF-1 decreased p27 expres-
sion via up-regulation of Skp2. Moreover, chemotherapeutic drug
trastuzumab (also known as Herceptin) decreased the expression
level of Skp2, whereas this decrease was attenuated by IGF-1 in
various breast cancer cells (Lu et al., 2004). Furthermore, IGF-
1-mediated reduction in p27 protein mediated via increased Skp2
expression involves the activation of PI3K pathway, suggesting that
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Skp2 could be an attractive target for the treatment of human
cancer by attenuating multiple other growth signaling pathways.
PPARγ AND ITS RELATIONSHIP WITH Skp2
Peroxisome proliferator-activated receptor-γ, a ligand-activated
transcription factor, has been demonstrated to provoke andmedi-
ate anti-inﬂammatory signaling (Schmidt et al., 2010). PPARγ
binds to PPREs (peroxisome proliferators response elements) as a
heterodimer with members of the RXR (retinoid X receptor) sub-
family, leading to the regulation of target gene expression (Schmidt
et al., 2010). It is widely accepted that PPARγ is a tumor suppressor
protein because it initiates a number of anti-neoplastic processes
such as arresting the cell cycle, causing cell differentiation, inhi-
bition of angiogenesis as well as induction of apoptosis (Schmidt
et al., 2010). It has been observed that PPARγ induced the expres-
sion of PTEN in breast cancer cell lines, possibly by binding to
putative PPREs, resulting in Akt phosphorylation and reduced cell
proliferation (Patel et al., 2001; Bonoﬁglio et al., 2005). However,
one study demonstrated that down-regulation of PPARγ sup-
pressed cell growth and induced apoptosis inMCF-7 breast cancer
cells (Zaytseva et al., 2008), arguing that the tumor suppressive role
of PPARγ could be cell-type or cellular context dependent.
Recently, PPARγ has been found to regulate Skp2 expression
in human cancers including breast cancer (Wei et al., 2007; Meng
et al., 2010). For example, thiazolidinediones (TZD), an agonist
of PPARγ, have been found to down-regulate Skp2 with accumu-
lation of its substrate p27 in prostate cancer (Wei et al., 2007).
More recently, PPARγ overexpression was reported to suppress
Skp2 levels. More importantly, the inverse correlation between the
expression of PPARγ and Skp2was identiﬁed in both breast cancer
cell lines and human breast cancer specimens (Meng et al., 2010).
Consistent with this, PPARγ overexpression inhibited the expres-
sion of Skp2 at both mRNA and protein levels, leading to reduced
cell proliferation and induction of apoptosis (Meng et al., 2010).
Furthermore, overexpression of Skp2 partially abrogates PPARγ’s
pro-apoptotic and anti-proliferative abilities (Meng et al., 2010),
suggesting that anti-neoplastic role of PPARγ could in part be
mediated through deregulation of Skp2 expression in breast can-
cer. However, more studies are required to fully understand how
PPARγ regulates Skp2 signaling pathway in human breast cancer.
THE ROLE OF FoxP3 WITH RESPECT TO Skp2 SIGNALING
TheFoxP3 (ForkheadboxP3), anX-linked tumor suppressor gene,
is amember of the forkhead box/winged-helix transcription factor
family (Wang et al., 2010a). FoxP3 is highly expressed in regula-
tory T cells, behaving as a master regulator in the development
and differentiation of regulatory T cells. In recent years, it has
been shown that FoxP3 is frequently inactivated in many human
cancers such as prostate cancer, ovarian cancer, and breast can-
cer (Zuo et al., 2007b; Wang et al., 2009; Zhang and Sun, 2010).
For example, overexpression of FoxP3 inhibited cell proliferation,
decreased cell migration, and reduced cell invasion in ovarian can-
cer (Zhang and Sun, 2010). In addition, FoxP3 retarded prostate
tumorigenesis through inhibition of oncogene Myc (Wang et al.,
2009). Moreover, FoxP3 has been identiﬁed as a transcriptional
repressor of the HER2 oncogene (Zuo et al., 2007b). Interestingly,
FoxP3 also suppressed growth and induced cell death in breast
cancer cell line without HER2 overexpression (Zuo et al., 2007b),
indicating that FoxP3 may affect other pathways that are involved
in breast cancer. Indeed, Zhang et al. found that FoxP3 is a novel
transcriptional repressor of Skp2 in human breast cancer (Zuo
et al., 2007a). Overexpression of FoxP3 inhibited Skp2 expression
with increased p27 in breast cancer cells, while down-regulation of
FoxP3 in human mammary epithelial cells increased Skp2 levels
(Zuo et al., 2007a). This ﬁnding has been further supported by
the observed inverse correlation between FoxP3 and Skp2 levels
in primary breast cancer samples (Zuo et al., 2007a). Moreover,
down-regulation of Skp2 was critical for FoxP3-mediated growth
inhibition in breast cancer cells (Zuo et al., 2007a), demonstrat-
ing that FoxP3 is a Skp2 repressor in breast cancer. However, how
FoxP3 regulates Skp2 expression andwhether this regulation could
be exploited for ﬁghting the battle against breast cancerwill require
further in-depth investigations.
Skp2 INHIBITION IS A NOVEL STRATEGY FOR BREAST
CANCER TREATMENT
Since Skp2 is frequently ampliﬁed and overexpressed in human
breast cancer, Skp2 could be a potential molecular target for
breast cancer therapy (Ohta and Fukuda, 2004). Therefore, inhi-
bition of Skp2 may be a novel strategy for the prevention and/or
treatment of breast cancer. To this end, several small molecule
inhibitors to block Skp2 expression have been developed by a high-
throughput screening (Chen et al., 2008;Rico-Bautista et al., 2010).
For example, a small molecular inhibitor CpdA (Compound A),
which blocks the recruitment of Skp2 to the SCF ligase, caused
cell cycle arrest, cell growth inhibition, and apoptosis in multiple
myeloma cells (Chen et al., 2008). Moreover, one chemical com-
pound known as SMIP0004 was found to down-regulate Skp2
and subsequently caused p27 stabilization in prostate cancer cells
(Rico-Bautista et al., 2010).Unfortunately, speciﬁc drugs that inac-
tivate Skp2 in breast cancer are unavailable so far, although we
believe that there is renewed interest in developing Skp2 inhibitors
for breast cancer treatment.
It is noteworthy that several natural compounds has been
found to down-regulate Skp2 expression in human cancers
including breast cancer (Huang et al., 2011). For example, cur-
cumin, lycopene, pentagalloylglucose, and quercetin inhibited
Skp2 expression, leading to cell growth inhibition and cell cycle
arrest through increased FOXO1 in breast cancer cells (Huang
et al., 2011). ATRA (all-trans retinoic acid) promoted the ubiqui-
tination of Skp2 in breast cancer cell lines, leading to cell cycle
arrest (Dow et al., 2001). Consistent with this notion, overex-
pression of Skp2 promotes resistance to ATRA and prevents p27
accumulation in breast cancer cells (Dow et al., 2001). Hsu et al.
(2011) found that gallic acid markedly reduced cell growth of
human breast cancer cells and induced cell cycle arrest by inhibi-
tion of Skp2 and attenuation of Skp2–p27 association as well as
reduction of p27 ubiquitination. Huang et al. (2008) reported that
EGCG (Epigallocatechin-3-gallate), the main constituent of green
tea, inhibited human breast cancer cell growth in part through
down-regulation of Skp2 expression and accumulation of p27.
Furthermore, both tamoxifen and paclitaxel signiﬁcantly and syn-
ergistically enhanced cell growth inhibition by EGCG mediated
through the down-regulation of Skp2 expression in breast cancer
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cells (Huang et al., 2008). Interestingly, the inhibition of Skp2 was
not always correlated with increased p27 expression, indicating
that EGCG-dependent Skp2 down-regulation could reduce cell
growth via other downstream pathway(s) (Huang et al., 2008).
These published data provides strong evidence in support of
the idea that inhibition of Skp2 may be a promising therapeutic
strategy for the treatment of human breast cancer.
CONCLUSION AND OVERALL PERSPECTIVES
In this short review article, we have provided succinct informa-
tion as to the state of our knowledge on the role of Skp2 in human
breast cancer. However, it is worth mentioning that the critical
roles for Skp2 as an oncoprotein in human cancer progression are
largely uncertain, although studies establishing the relationship
between Skp2 and cancer have been burst onto the scene in recent
years, and several groups have found that multiple genes includ-
ing PI3K/Akt, ERK, mTOR, and FoxP3, could regulate the Skp2
expression (Figure 2). Skp2 has been revealed as a novel target for
the prevention and/or treatment of human cancers including but
not limited to breast cancer. Therefore, the development of agents
for speciﬁcally targeting Skp2 is likely to have a signiﬁcant thera-
peutic impact on the treatment of human cancers. Furthermore,
here we summarized that several compounds, especially natural
compounds that could speciﬁcally target Skp2 may act as anti-
cancer drugs. Due to non-toxic features, inhibition of Skp2 by
natural agents could be a novel and safer approach for empower-
ing anticancer therapy. However, further pre-clinical studies are
needed to ﬁnd the right combinations with chemotherapeutic
drugs toward better treatment of human mammary malignan-
cies. We hope that this article could promote further study for the
development of speciﬁc inhibitors/antagonists for targeted inacti-
vation of Skp2 for cancer therapy by either single agent or by using
a combinational approach. In conclusion, targeted inactivation of
Skp2 would likely become a novel newer strategy for the preven-
tion of tumor progression and/or successful treatment of human
malignancies including breast cancer in the future.
FIGURE 2 | Diagram of Skp2’s cross-talks with other major signaling
pathways in breast cancer. PI3K/Akt, mTOR, PPARγ, ERK, FoxP3, and IGF
regulate the expression of Skp2 in the breast cancer. Chemical compounds
including Skp2 inhibitors and natural agents inhibit cell growth and induce
apoptosis through down-regulation of Skp2 expression in breast cancer.
Skp2, S-phase kinase associated protein 2; ERK, extracellular
signal-regulated kinase; IGF-1, insulin-like growth factor-1; FoxP3, forkhead
box P3; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol
3-kinase; PPARγ, peroxisome proliferator-activated receptor-γ.
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